https://wiki.docmoates.com/index.php?action=history&feed=atom&title=Flecainide Flecainide - Revision history 2026-06-17T15:49:57Z Revision history for this page on the wiki MediaWiki 1.42.4 https://wiki.docmoates.com/index.php?title=Flecainide&diff=3977&oldid=prev Docmoates: NCLEX nursing pharmacology monographs — batch import 2026-06-17T13:37:16Z <p>NCLEX nursing pharmacology monographs — batch import</p> <p><b>New page</b></p><div>&lt;div style=&quot;border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;&quot;&gt;<br /> &#039;&#039;Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and &#039;&#039;&#039;must be verified against current manufacturer labeling before clinical use&#039;&#039;&#039;. This is educational content, not prescribing guidance.&#039;&#039;<br /> &lt;/div&gt;<br /> <br /> &#039;&#039;&#039;Flecainide&#039;&#039;&#039; (brand name Tambocor) &amp;mdash; Antiarrhythmic; Class IC antiarrhythmic.<br /> <br /> == Identification ==<br /> * &#039;&#039;&#039;Therapeutic class:&#039;&#039;&#039; Antiarrhythmic.<br /> * &#039;&#039;&#039;Pharmacologic class:&#039;&#039;&#039; Class IC antiarrhythmic.<br /> <br /> == Pharmacology ==<br /> * &#039;&#039;&#039;Mechanism of action:&#039;&#039;&#039; Strongly blocks sodium channels, slowing cardiac conduction.<br /> * &#039;&#039;&#039;Onset / peak / duration:&#039;&#039;&#039; Peak 1 to 6 hours; duration about 12 hours.<br /> * &#039;&#039;&#039;Half-life / therapeutic level:&#039;&#039;&#039; Half-life 12 to 27 hours; no routine level.<br /> <br /> == Clinical use ==<br /> * &#039;&#039;&#039;Indications:&#039;&#039;&#039; Paroxysmal atrial fibrillation and supraventricular tachycardia in patients without structural heart disease.<br /> * &#039;&#039;&#039;Usual dose, route, frequency:&#039;&#039;&#039; 50 to 150 mg PO every 12 hours.<br /> * &#039;&#039;&#039;Maximum dose / adjustments:&#039;&#039;&#039; Max about 400 mg/day; reduce in renal impairment.<br /> <br /> == Safety ==<br /> * &#039;&#039;&#039;Contraindications:&#039;&#039;&#039; Structural or ischemic heart disease, second or third degree block, cardiogenic shock.<br /> * &#039;&#039;&#039;Black box warning:&#039;&#039;&#039; Associated with increased mortality in patients with recent MI or structural heart disease (based on the CAST trial); limit to patients without structural heart disease.<br /> * &#039;&#039;&#039;Interactions:&#039;&#039;&#039; Other antiarrhythmics, beta blockers, digoxin (raises level), CYP2D6 inhibitors.<br /> * &#039;&#039;&#039;Pregnancy / lactation:&#039;&#039;&#039; Use only if clearly needed.<br /> * &#039;&#039;&#039;High-alert:&#039;&#039;&#039; No.<br /> <br /> == Adverse effects ==<br /> * &#039;&#039;&#039;Common side effects:&#039;&#039;&#039; Dizziness, visual disturbance, dyspnea, headache.<br /> * &#039;&#039;&#039;Serious effects to report:&#039;&#039;&#039; New or worsening arrhythmia, heart failure symptoms.<br /> * &#039;&#039;&#039;Antidote / reversal:&#039;&#039;&#039; Supportive care.<br /> <br /> == Nursing process ==<br /> * &#039;&#039;&#039;Assessment before administration:&#039;&#039;&#039; ECG, structural heart disease screening, electrolytes, renal function.<br /> * &#039;&#039;&#039;Interventions during therapy:&#039;&#039;&#039; Confirm absence of structural heart disease; monitor ECG.<br /> * &#039;&#039;&#039;Monitor:&#039;&#039;&#039; ECG and QRS width, heart rhythm, renal function.<br /> * &#039;&#039;&#039;Evaluation / expected outcome:&#039;&#039;&#039; Maintained normal rhythm.<br /> <br /> == Patient teaching ==<br /> * &#039;&#039;&#039;Patient teaching:&#039;&#039;&#039; Keep follow-up ECGs; report palpitations.<br /> * &#039;&#039;&#039;Notify provider if:&#039;&#039;&#039; Palpitations, fainting, shortness of breath.<br /> * &#039;&#039;&#039;Administration tips:&#039;&#039;&#039; Consistent every-12-hour timing.<br /> <br /> [[Category:Antiarrhythmics and Specialty Cardiac Agents]]</div> Docmoates